Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 2, 2007, Pages 321-328

  Rayes, J ^a   Hommais, A ^a   Legendre, P ^a   Tout, H ^a   Veyradier, A ^a   Obert, B ^a   Ribba, A S ^a   Girma, Jean Pierre ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

ADAMTS 13; Mutations; Von Willebrand disease; Von Willebrand factor

Indexed keywords

ARGININE; GLUTAMIC ACID; GLYCINE; HISTIDINE; ISOLEUCINE; LYSINE; METHIONINE; PHENYLALANINE; PROLINE; RECOMBINANT PROTEIN; SERINE; SODIUM CHLORIDE; THREONINE; TRYPTOPHAN; VALINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE PREDISPOSITION; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIC STRENGTH; MOLECULAR WEIGHT; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; THROMBOCYTE; VON WILLEBRAND DISEASE; WILD TYPE;

ADAM PROTEINS; DIMERIZATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION, MISSENSE; OSMOLAR CONCENTRATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 33846445722     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02296.x     Document Type: Article

References (47)

1. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003; 10: 142-9.
2. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005; 106: 11-7.
3. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
4. Zheng XL, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
5. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand Factor. Cleavage is present in normal individuals, increased in type IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 947-51.
6. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-10.
7. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand-Factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-82.
8. Moake JL. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 4-14.
9. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
10. Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: A 2004 update. Semin Hematol 2005; 42: 15-28.
11. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type-IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
12. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: Inhibition by doxycycline and by monoclonal antibody VP-1. Blood 1997; 89: 1954-62.
13. Sadler JE. Willebrand factor: Two sides of a coin. J Thromb Haemost 2005; 3: 1702-9.
14. Meyer D, Fressinaud E, Hilbert L, Ribba AS, Lavergne JM, Mazurier C. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 2001; 14: 349-64.
15. Ribba AS, Voorberg J, Meyer D, Pannekoek H, Pietu G. Characterization of recombinant von Willebrand factor corresponding to mutations in Type-IIA and Type-IIB von Willebrand disease. J Biol Chem 1992; 267: 23209-15.
16. Ribba AS, Christophe O, Derlon A, Cherel G, Siguret V, Lavergne JM, Girma JP, Meyer D, Pietu G. Discrepancy between IIA-phenotype and IIB-genotype in a patient with a variant of von Willebrand disease. Blood 1994; 83: 833-41.
17. Hilbert L, Gaucher C, Abgrall JF, Parquet A, Trzeciak C, Mazurier C. Identification of new type 2B von Willebrand disease mutations: Arg543Gln, Arg545Pro and Arg578Leu. Br J Haematol 1998; 103: 877-84.
18. Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type-IIB -candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein-Ib binding sequences. J Clin Invest 1991; 87: 1220-6.
19. Hilbert L, Fressinaud E, Ribba AS, Meyer D, Mazurier C. Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor. Thromb Haemost 2002; 87: 635-40.
20. Ajzenberg N, Ribba AS, RastegarLari G, Meyer D, Baruch D. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood 2000; 95: 3796-803.
21. Hommais A, Stepanian A, Fressinaud E, Mazurier C, Meyer D, Girma JP, Ribba AS. Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion. J Thromb Haemost 2006; 4: 148-57.
22. Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF. Blood 1995; 86: 1010-8.
23. Veyradier A, Jumilly AL, Ribba AS, Obert B, Houllier A, Meyer D, Girma JP. New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor. Thromb Haemost 1999; 82: 134-9.
24. Obert B, Houllier A, Meyer D, Girma JP. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib. Blood 1999; 93: 1959-68.
25. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999; 82: 1382-5.
26. Hilbert L, Gaucher C, De Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697 -> Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
27. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103: 607-12.
28. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 30136-41.
29. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
30. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
31. Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJW, Bracke M, Furlan M, deGroot PG, Sixma JJ, Vink T. Recombinant vWF type 2A mutants R834Q and R834W show a defect in mediating platelet adhesion to collagen, independent of enhanced sensitivity to a plasma protease. Thromb Haemost 1999; 81: 976-83.
32. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 1654-61.
33. De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di Stasio E, Mannucci PM. Role of chloride ions in the modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 2005; 280: 23295-302.
34. Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006; 281: 850-7.
35. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular mapping of the chloride binding site in von Willebrand factor (VWF): Energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem 2006; 281: 30400-11.
36. Hassenpflug WA, Budde U, Obser T, Angerhaus D, Drewke E, Schneppenheim S, Schneppenheim R. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006; 107: 2339-45.
37. Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA. Adamts13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281: 1555-63.
38. Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 2004; 10: 259-70.
39. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, Lopez JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278: 29633-9.
40. Zhang W, Motto D, Ginsburg D. ADAMTS-13 binds VWF via its C-terminal CUB2 domain. Blood 2004; 104: 39a.
41. Tao Z, Peng Y, Nolasco L, Cal S, Lopez-Otin C, Li R, Moake JL, Lopez JA, Dong JF. Role of the CUB-1 domain in docking ADAMTS-13 to unusually large Von Willebrand factor in flowing blood. Blood 2005; 106: 4139-45.
42. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280: 21773-8.
43. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-6.
44. Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin anchors newly released ultra-large von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103: 2150-6.
45. Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies. Blood 2006; 107: 3922-4.
46. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9.
47. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004; 101: 10578-83.